JERSEY CITY, N.J., Dec. 17, 2015 /PRNewswire/ -- TrialScope, the global leader in clinical trial transparency and compliance solutions, today announced that the company recently conducted its Clinical Trial Transparency Leadership Forum, part of TrialScope's Transparency Leadership Series which is designed to bring leaders in life sciences companies together to discuss and debate current and emerging clinical trial transparency and compliance topics.
Each of the Forum programs are developed around specific topics or themes that are timely and important to compliance leaders. The December Forum included discussions of global disclosure performance and was highlighted by a presentation by Jennifer Miller, PhD. Assistant Professor, Division of Medical Ethics, NYU School of Medicine's Department of Population Health and President of Bioethics International entitled, "The Good Pharma Scorecard". Thomas Wicks, Chief Strategy Officer at TrialScope also presented findings from TrialScope's Clinical Trial Disclosure Maturity Model. The presentations and ensuing discussions highlighted the importance of measuring disclosure performance as well as the marketplace perception of such performance while also noting the challenges that most life sciences companies face when developing global disclosure policies.
Mike Forgash, CEO, TrialScope, commented, "TrialScope's Transparency Leadership Forum was an exceptional event that enabled industry leaders to step away from their desks and talk about important strategic and operational topics that impact clinical trial transparency programs with industry peers. The program is founded on the idea that these leaders can share their rationales, best practices, and challenges in an intimate setting with the goal of learning and improving existing disclosure performance."
Thomas Wicks, Chief Strategy Officer, noted, "The Transparency Leadership Series provides a unique opportunity for our industry peers to collaborate in a non-competitive environment. We purposely design plenty of discussion time into the program so participants get maximum value from their time together. In this Forum, we addressed disclosure performance as a collection of important metrics that tell a sponsor's compliance story. We also heard the concern about how that story is viewed by the market and the potential impact it has on brand integrity. We plan to offer similar programs in the New Year and will look to current participants to help us shape the agenda and prioritize discussion topics."
About TrialScope
TrialScope simplifies the complexities of clinical transparency management. TrialScope is a proven solution that has been implemented successfully and rigorously tested in the most complex environments with solutions that are currently implemented at 13 of the top 30 global clinical trial sponsors, including 6 of the top 10. The company's market-driven solutions and expertise enable sponsors to improve their clinical trial process, mitigate registry and lifecycle risk, and ultimately achieve greater compliance. TrialScope technology is offered via a validation-ready SaaS platform hosted in a private cloud.
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.